PATENT CLAIM ANALYSIS

Application Number: 15562825
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-04
Patent Classification: ["544", "183000"]

Abstract:
The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

Claim (Index 36):
A pharmaceutical composition comprising the compound or enantiomer, diastereoisomer, geometric isomer, solvate or pharmaceutically acceptable salt thereof according to  claim 18  and at least one pharmaceutically acceptable carrier, the pharmaceutical composition is tablet, suppository, dispersible tablet, enteric tablet, chewable tablet, orally disintegrating tablet, capsule, sugar coated tablet, granule, dry powder, oral solution, small volume injection, or freeze-dried powder injection, the pharmaceutically acceptable carrier includes one or more substances selected from diluents, solubilizers, disintegrants, suspending agents, lubricants, binders, fillers, flavoring agents, sweetening agents, antioxidants, surfactants, preservatives, encapsulants and pigments.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 94.0
- Lexical Diversity: 1.36667
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15812142', '15750704', '16470111', '15314599', '16326976']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.798760543641609
- 35 USC 102 Novelty (BERT): 0.5316312117024892
- Combined Prediction Score: 0.772047610447697
- Mean Citation Score: 357.22619
- Max Citation Score: 380.52487
- Similarity Product: 272.19643423785993

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test